Neurology 1999;52:1338
© 1999 American Academy of Neurology
Articles
A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children
R. D. Elterman, MD,
T. A. Glauser, MD,
E. Wyllie, MD,
R. Reife, MD,
S.-C. Wu, PhD,
G. Pledger, PhD and
the Topiramate YP Study Group*
From the Dallas Pediatric Neurology Associates (Dr. Elterman), Dallas, TX; Division of Pediatric Neurology (Dr. Glauser), Children’s Hospital Medical Center, Cincinnati, OH; Cleveland Clinic Foundation (Dr. Wyllie), OH; Corporate Office Science and Technology (Dr. Reife), Johnson & Johnson, New Brunswick, NJ; The R.W. Johnson Pharmaceutical Research Institute (Drs. Wu and Pledger), Raritan, NJ; and the Topiramate YP Study Group.
Address correspondence and reprint requests to Dr. Roy Elterman, Dallas Pediatric Neurology Associates, 12801 North Central Expressway, Plaza 3, Suite 580, Dallas, TX 75230.
OBJECTIVE: To evaluate the efficacy and safety of topiramate 6 mg/kg/day in children (age 2 to 16 years) as adjunctive therapy for uncontrolled partial-onset seizures with or without secondarily generalized seizures in a multicenter, randomized, double-blind, placebo-controlled trial.
METHODS: Patients with at least six partial-onset seizures during the 8-week baseline phase were treated with either topiramate (n = 41) or placebo (n = 45) for 16 weeks.
RESULTS: Topiramate-treated patients had a greater median percent reduction from baseline in average monthly partial-onset seizure rate than placebo-treated patients (33.1% versus 10.5%, p = 0.034), a greater proportion of treatment responders (i.e., patients with a  50% seizure rate reduction; 16 of 41 [39%] versus 9 of 45 [20%], p = 0.080), and patients with a 75% seizure rate reduction (7 of 41 [17%] versus 1 of 45 [2%], p = 0.019), and better parental global evaluations of improvement in seizure severity (p = 0.019). Emotional lability (12% versus 4%), fatigue (15% versus 7%), difficulty with concentration or attention (12% versus 2%), and forgetfulness/impaired memory (7% versus 0%) were more frequent among topiramate-treated than placebo-treated patients. Most treatment-emergent adverse events were mild or moderate in severity. No topiramate-treated patients discontinued the study due to adverse events.
CONCLUSIONS: Topiramate was safe and effective in the treatment of partial-onset seizures in children.
This article has been cited by other articles:
|
|
|
|
 
V. Degos, G. Loron, J. Mantz, and P. Gressens
Neuroprotective Strategies for the Neonatal Brain
Anesth. Analg.,
June 1, 2008;
106(6):
1670 - 1680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Glauser, D. J. Dlugos, W. E. Dodson, A. Grinspan, S. Wang, S.-C. Wu, and and the EPMN-106/INT-28 Investigators
Topiramate Monotherapy in Newly Diagnosed Epilepsy in Children and Adolescents
J Child Neurol,
June 1, 2007;
22(6):
693 - 699.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. A. Glauser, R. Ayala, R. D. Elterman, W. G. Mitchell, C. B. Van Orman, L. J. Gauer, Z. Lu, and on behalf of the N159 Study Group
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures
Neurology,
June 13, 2006;
66(11):
1654 - 1660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Chiron, S. Tonnelier, E. Rey, M.-L. Brunet, A. Tran, P. d'Athis, J. Vincent, O. Dulac, and G. Pons
Stiripentol in Childhood Partial Epilepsy: Randomized Placebo-Controlled Trial with Enrichment and Withdrawal Design
J Child Neurol,
June 1, 2006;
21(6):
496 - 502.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Biton, B. F. D. Bourgeois, and for the YTC/YTCE Study Investigators
Topiramate in Patients With Juvenile Myoclonic Epilepsy
Arch Neurol,
November 1, 2005;
62(11):
1705 - 1708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rey, C. Bulteau, J. Motte, A. Tran, Y. Sturm, J. D'Souza, S. Markabi, G. Pons, and O. Dulac
Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy
J. Clin. Pharmacol.,
November 1, 2004;
44(11):
1290 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Glauser
Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients
J Child Neurol,
August 1, 2004;
19(1_suppl):
S25 - S38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al.
Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
Neurology,
April 27, 2004;
62(8):
1261 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Loring and K. J. Meador
Cognitive side effects of antiepileptic drugs in children
Neurology,
March 23, 2004;
62(6):
872 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Wheless, W. Neto, and S. Wang
Topiramate, Carbamazepine, and Valproate Monotherapy: Double-Blind Comparison in Children With Newly Diagnosed Epilepsy
J Child Neurol,
February 1, 2004;
19(2):
135 - 141.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Rigoulot, E. Koning, A. Ferrandon, and A. Nehlig
Neuroprotective Properties of Topiramate in the Lithium-Pilocarpine Model of Epilepsy
J. Pharmacol. Exp. Ther.,
February 1, 2004;
308(2):
787 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gross-Tsur and R. S. Shalev
Reversible language regression as an adverse effect of topiramate treatment in children
Neurology,
January 27, 2004;
62(2):
299 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Glauser
Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients
J Child Neurol,
January 1, 2004;
19(1_suppl):
S25 - S38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Mula, M. R. Trimble, P. Thompson, and J. W.A.S. Sander
Topiramate and word-finding difficulties in patients with epilepsy
Neurology,
April 8, 2003;
60(7):
1104 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Watemberg, H. Goldberg-Stern, B. Ben-Zeev, I. Berger, R. Straussberg, S. Kivity, U. Kramer, N. Brand, and T. Lerman-Sagie
Clinical Experience With Open-Label Topiramate Use in Infants Younger Than 2 Years of Age
J Child Neurol,
April 1, 2003;
18(4):
258 - 262.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. G. Jarrar and J. R. Buchhalter
Therapeutics in Pediatric Epilepsy, Part 1: The New Antiepileptic Drugs and the Ketogenic Diet
Mayo Clin. Proc.,
March 1, 2003;
78(3):
359 - 370.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Forderreuther, M Mayer, and A Straube
Authors' Reply: Treatment of Cluster Headache with Topiramate: Effects and Side-Effects in Five Patients
Cephalalgia,
February 1, 2003;
23(1):
70 - 70.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.G. Gilliam, F. Veloso, M.A.M. Bomhof, S.K. Gazda, V. Biton, J.P. Ter Bruggen, W. Neto, C. Bailey, G. Pledger, and S.-C. Wu
A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy
Neurology,
January 28, 2003;
60(2):
196 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Glauser
Integrating clinical trial data into clinical practice
Neurology,
June 25, 2002;
58(12_suppl_7):
S6 - S12.
[Full Text]
|
|
|
|
|
|
|
S Forderreuther, M Mayer, and A Straube
Treatment of Cluster Headache with Topiramate: Effects and Side-Effects in Five Patients
Cephalalgia,
April 1, 2002;
22(3):
186 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bebin
Pediatric Partial and Generalized Seizures
J Child Neurol,
January 1, 2002;
17(1_suppl):
S65 - S69.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Schwabe and J. W. Wheless
Clinical Experience With Topiramate Dosing and Serum Levels in Children 12 Years or Under With Epilepsy
J Child Neurol,
November 1, 2001;
16(11):
806 - 808.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Gilman and M. Duchowny
Topiramate in Childhood Epilepsy: Past, Present, and Future
J Child Neurol,
December 1, 2000;
15(1_suppl):
S1 - S2.
[PDF]
|
|
|
|
|
|
|
K. D. Holland and E. Wyllie
Use of Topiramate in Localization-Related Epilepsy in Children
J Child Neurol,
December 1, 2000;
15(1_suppl):
S3 - S6.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. W. Wheless
Use of Topiramate in Childhood Generalized Seizure Disorders
J Child Neurol,
December 1, 2000;
15(1_suppl):
S7 - S13.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. M. Levisohn
Safety and Tolerability of Topiramate in Children
J Child Neurol,
December 1, 2000;
15(1_suppl):
S22 - S26.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. F.D. Bourgeois
Pharmacokinetics and Pharmacodynamics of Topiramate
J Child Neurol,
December 1, 2000;
15(1_suppl):
S27 - S30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P J Thompson, S A Baxendale, J S Duncan, and J W A S Sander
Effects of topiramate on cognitive function
J. Neurol. Neurosurg. Psychiatry,
November 1, 2000;
69(5):
636 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. O. Tatum IV, R. Galvez, S. Benbadis, and E. Carrazana
New Antiepileptic Drugs: Into the New Millennium
Arch Fam Med,
November 1, 2000;
9(10):
1135 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Glauser, M. Nigro, R. Sachdeo, L. A. Pasteris, S. Weinstein, B. Abou-Khalil, L. M. Frank, A. Grinspan, T. Guarino, D. Bettis, et al.
Adjunctive therapy with oxcarbazepine in children with partial seizures
Neurology,
June 27, 2000;
54(12):
2237 - 2244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
